Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, November 11 at 2:00 PM ET

Register Free →

This Sources Sought opportunity was posted on April 3, 2013. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Q--Breast Cancer Test

Awarded
VA24613Q0987Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

AI Contract Overview

Show more

This Sources Sought notice, solicitation number VA24613Q0987, is issued to identify capable providers for the procurement of six Oncotype DX breast cancer tests. The requirement focuses on a 21-gene assay used by the Durham VAMC to provide individualized predictions of chemotherapy benefit and 10-year distant recurrence for women with early-stage invasive breast cancer. This announcement is for market research purposes only and is not a formal request for bids, quotes, or proposals. Interested parties must submit a capability statement by April 5, 2013, at 1:00pm EST to [email hidden]. Submissions must include the company name, address, business size, and applicable socioeconomic categories, along with evidence of the firm's ability to meet the technical requirements. The government will not provide compensation for any costs incurred during the submission of this voluntary information.

General Info

Agency

N/A

Contract Value

$17,080

NAICS

541711 - Research and Development in Biotechnology

Place of Performance

DURHAM VAMC;508 Fulton ST.;Durham , NC 27705-3875 USA, CA, USA

Set-Aside

NONE

Award Issued Date

Documents

0

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PhaseAwarded
Posted

Sources Sought

Awarded

Contract was awarded

Submission Closed

Find active opportunities like this

Get full access to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyN/A
ContactsNo contacts available
OfficeN/A
Organization / Agency
N/A
Office AddressN/A
ContactsNo contact information available

Full Description

Show more
This "Source of Sought" is to determine sources for breast cancer test and/or procurement of services for a quantity of 6 Oncotype DX. This is not a request for bids, quotes, or proposals. All responsible sources may submit a capability statement which shall be considered by the agency. All information submitted in response to this announcement is voluntary; the Government will not pay for information requested nor will it compensate any respondent for any cost incurred in developing information provided to the Government. Durham VAMC breast cancer studies is based off a 21-gene assay that provides an individualized prediction of chemotherapy benefit and 10-year distant recurrence to inform adjuvant treatment decisions in certain women with early-stage invasive breast cancer. The 21-gene panel used to develop the Recurrence Score® Algorithm. Proliferation: Ki-67, STK15, Survivin, Cyclin B1, MYBL2. Invasion: Stromelysin 3, Cathepsin L2. HER2: GRB7, HER2. Estrogen: ER, PR, Bcl-2, SCUBE2. Other: GSTM1, CD68, BAG1. Reference: Beta-action, GAPDH, RPLPO, GUS TFRC. Interested parties submitting a response to this inquiry must include the following information: name and address of company; business size (large or small); identify applicable socioeconomic categories and any pertinent information which demonstrates firms ability to meet the above requirement. All responses shall be submitted no later than April 5, 2013 at 1:00pm EST. Responses shall be emailed to: contact@example.gov

Earlier notices in this NAICS code

Posted before this notice, open and closed

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS